Abstract:Prostate cancer can be lethal in advanced stages, for which chemotherapy may become the only viable therapeutic option. While there is no clear clinical management strategy fitting all patients, cytotoxic chemotherapy with docetaxel is currently regarded as the gold standard. However, tumors may regain activity after treatment conclusion and become resistant to docetaxel. This situation calls for new delivery strategies and drug compounds enabling an improved therapeutic outcome. Combination of docetaxel with antiangiogenic therapy has been considered a promising strategy. Bevacizumab is the most common antiangiogenic drug, but clinical studies have not revealed a clear benefit from its combination with docetaxel. Here, we capitalize on our prior work on mathematical modeling of prostate cancer growth subjected to combined cytotoxic and antiangiogenic therapies, and propose an optimal control framework to robustly compute the drug-independent cytotoxic and antiangiogenic effects enabling an optimal therapeutic control of tumor dynamics. We describe the formulation of the optimal control problem, for which we prove the existence of at least a solution and determine the necessary first-order optimality conditions. We then present numerical algorithms based on isogeometric analysis to run a preliminary simulation study over a single cycle of combined therapy. Our results suggest that only cytotoxic chemotherapy is required to optimize therapeutic performance and we show that our framework can produce superior solutions to combined therapy with docetaxel and bevacizumab. We also illustrate how the optimal drug-naïve cytotoxic effects computed in these simulations may be successfully leveraged to guide drug production and delivery strategies by running a nonlinear least-square fit of protocols involving docetaxel and a new design drug. In the future, we believe that our optimal control framework may contribute to accelerate experimental research on chemotherapeutic drugs for advanced prostate cancer and ultimately provide a means to design and monitor its optimal delivery to patients.

Optimal control in cancer immunotherapy by the application of particle swarm optimization

Model reference adaptive control based on particle swarm optimization algorithm

An Optimal Control Strategy for Mathematically Modeling Cancer Combination Therapy

An Iterative Multi-Objective Particle Swarm Optimization-Based Control Vector Parameterization for State Constrained Chemical and Biochemical Engineering Problems

Process Control Parameters Optimal Selection Based on Particle Swarm Algorithm

Dual therapy of cancer using optimal control supported by swarm intelligence

A Mathematical Model of Tumor‐Immune and Host Cells Interactions with Chemotherapy and Optimal Control

Multi-objective optimal chemotherapy control model for cancer treatment

On the optimal control problem for a model of the synergy of chemo‐ and immunotherapy

A Mathematical Tumor Model with Immune Resistance and Drug Therapy: An Optimal Control Approach

Optimal dosage protocols for mathematical models of synergy of chemo- and immunotherapy

Optimal control in reducing side effects during and after chemotherapy of solid tumors

Optimal control of combination immunotherapy for a virtual murine cohort in a glioblastoma-immune dynamics model

Optimal drug application on stochastic cancer growth: an approach through path integral control

Optimal control for cancer treatment mathematical model using Atangana–Baleanu–Caputo fractional derivative

A Modified Particle Swarm Optimization Algorithm for Global Optimizations of Inverse Problems

Evolutionary Dynamics Optimal Research-Oriented Tumor Immunity Architecture

Combination of Direct Methods and Homotopy in Numerical Optimal Control: Application to the Optimization of Chemotherapy in Cancer

Cost-effectiveness Analysis of Optimal Strategy for Tumor Treatment

A Decision Making Approach for Chemotherapy Planning based on Evolutionary Processing

Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth